Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015
Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, Eva Segelov, Daniel G Haller, Cornelis JA Punt, Dirk Arnold, Christos S Karapetis, Niall C Tebbutt, Nick Pavlakis, Peter Gibbs, Jeremy D Shapiro
Expert Review of Anticancer Therapy | TAYLOR & FRANCIS LTD | Published : 2016
Australian authors have received honoraria and travel support to attend national and international meetings for colorectal cancer from Merck Serono, AMGEN, Roche and Sanofi Aventis. Subotheni Thavaneswaran has no disclosures. Disclosures for the international faculty are as follows; Prof Dr Cornelis Punt, advisor for Roche, Merck, Amgen, Bayer, Sanofi, Nordic Pharma; Dr Dirk Arnold Research Funding Roche; Prof Daniel Haller Consultant/honoraria, Sanofi-Aventis, Amgen, Genentech; Research funding Roche. The group meeting that enabled the material for this Review to be assembled was supported by an unrestricted educational grant from Roche provided to the 'Adelaide Colorectal Tumour Group' which facilitated the meeting. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.